Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

• Market cap: $1.26B
• 1 day: -12.56%
• 5 days: 10.11%
• 1 month: -12.56%
• 3 months: -12.56%
• 6 months: -12.56%
• Year to date: -12.56%
• 1 year: -12.56%
• 5 years: -12.56%
• 10 years: -12.56%
• Sector: Healthcare
• Industry: Biotechnology

About: Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.